Ratings Implantica AG

Equities

IMP A SDB

SE0014855029

Market Closed - Nasdaq Stockholm Other stock markets 16:24:20 26/04/2024 BST			5-day change	1st Jan Change
27.5 ^SEK	+0.18%		-5.17%	+15.06%

03-27	Implantica Submits Initial Module of US FDA Premarket Approval Application for GERD Medical Device	MT
03-27	Implantica Submits U.S. FDA Premarket Approval Application for RefluxStop® (first module)	CI

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
Thanks to a sound financial situation, the firm has significant leeway for investment.
Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
The company's "enterprise value to sales" ratio is among the highest in the world.
For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
IMPLANTICA AG	+15.06%	710M	-
SHOCKWAVE MEDICAL, INC.	+73.17%	12.38B	B-
PENUMBRA, INC.	-18.74%	7.92B	C+
MASIMO CORPORATION	+16.15%	7.2B	C-
GETINGE AB	+4.81%	5.84B	B
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.	+5.99%	5.07B	D+
APT MEDICAL INC.	+27.07%	4.53B	-
ASAHI INTECC CO., LTD.	-21.67%	3.88B	B-
INARI MEDICAL, INC.	-40.82%	2.23B	C
SKAN GROUP AG	+1.49%	2.02B	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes